↓ Skip to main content

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

Overview of attention for article published in BMC Musculoskeletal Disorders, May 2016
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
58 Dimensions

Readers on

mendeley
81 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
Published in
BMC Musculoskeletal Disorders, May 2016
DOI 10.1186/s12891-016-1082-z
Pubmed ID
Authors

Rieke Alten, Clifton O. Bingham, Stanley B. Cohen, Jeffrey R. Curtis, Sheila Kelly, Dennis Wong, Mark C. Genovese

Abstract

Patients with rheumatoid arthritis (RA), including those treated with biologics, are at increased risk of some vaccine-preventable infections. We evaluated the antibody response to standard 23-valent pneumococcal polysaccharide vaccine (PPSV23) and the 2011-2012 trivalent seasonal influenza vaccine in adults with RA receiving subcutaneous (SC) abatacept and background disease-modifying anti-rheumatic drugs (DMARDs). Two multicenter, open-label sub-studies enrolled patients from the ACQUIRE (pneumococcal and influenza) and ATTUNE (pneumococcal) studies at any point during their SC abatacept treatment cycle following completion of ≥3 months' SC abatacept. All patients received fixed-dose abatacept 125 mg/week with background DMARDs. A pre-vaccination blood sample was taken, and after 28 ± 3 days a final post-vaccination sample was collected. The primary endpoint was the proportion of patients achieving an immunologic response to the vaccine at Day 28 among patients without a protective antibody level to the vaccine antigens at baseline (pneumococcal: defined as ≥2-fold increase in post-vaccination titers to ≥3 of 5 antigens and protective antibody level of ≥1.6 μg/mL to ≥3 of 5 antigens; influenza: defined as ≥4-fold increase in post-vaccination titers to ≥2 of 3 antigens and protective antibody level of ≥1:40 to ≥2 of 3 antigens). Safety and tolerability were evaluated throughout the sub-studies. Pre- and post-vaccination titers were available for 113/125 and 186/191 enrolled patients receiving the PPSV23 and influenza vaccine, respectively. Among vaccinated patients, 47/113 pneumococcal and 121/186 influenza patients were without protective antibody levels at baseline. Among patients with available data, 73.9 % (34/46) and 61.3 % (73/119) met the primary endpoint and achieved an immunologic response to PPSV23 or influenza vaccine, respectively. In patients with pre- and post-vaccination data available, 83.9 % in the pneumococcal study demonstrated protective antibody levels with PPSV23 (titer ≥1.6 μg/mL to ≥3 of 5 antigens), and 81.2 % in the influenza study achieved protective antibody levels (titer ≥1:40 to ≥2 of 3 antigens) at Day 28 post-vaccination. Vaccines were well tolerated with SC abatacept with background DMARDs. In these sub-studies, patients with RA receiving SC abatacept and background DMARDs were able to mount an appropriate immune response to pneumococcal and influenza vaccines. NCT00559585 (registered 15 November 2007) and NCT00663702 (registered 18 April 2008).

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 81 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 15%
Student > Ph. D. Student 11 14%
Student > Master 9 11%
Student > Postgraduate 6 7%
Student > Bachelor 6 7%
Other 9 11%
Unknown 28 35%
Readers by discipline Count As %
Medicine and Dentistry 26 32%
Biochemistry, Genetics and Molecular Biology 4 5%
Agricultural and Biological Sciences 4 5%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Nursing and Health Professions 2 2%
Other 9 11%
Unknown 33 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 April 2021.
All research outputs
#15,376,252
of 22,875,477 outputs
Outputs from BMC Musculoskeletal Disorders
#2,458
of 4,055 outputs
Outputs of similar age
#210,145
of 337,044 outputs
Outputs of similar age from BMC Musculoskeletal Disorders
#56
of 77 outputs
Altmetric has tracked 22,875,477 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,055 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 337,044 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.